

# Medicare Supplement Insurance Underwriting Guide

For Agent and Home Office use only

NGAH\_MEDSUP 05/2018 © 2018. National Health Insurance Company. All Rights Reserved.

National General Accident & Health markets products underwritten by National Health Insurance Company, Integon National Insurance Company and Integon Indemnity Corporation.

# **Table of Contents**

| Contacts                                   | 2 |
|--|---|
| Hours of Operation                         | 2 |
| Introduction                               |   |
| New Business Guidelines                    | 3 |
| Eligibility Requirements                   | 3 |
| Replacements                               | 3 |
| Open Enrollment Guidelines                 | 4 |
| Guaranteed Issue Guidelines                | 4 |
| State Specific Guaranteed Issue Guidelines | 6 |
| Medicare Advantage (MA) Guidelines         | 6 |
| Enrollment Guidelines                      | 7 |
| Submitting the Application                 | 8 |
| Premium Payment                            |   |
| Required Forms                             |   |
| Agent Responsibilities                     |   |
| Underwriting Concepts                      |   |
| Underwriting Appeals                       |   |
| Reinstatements                             |   |
| Underwriting Guidelines                    |   |
| Drug List Information                      |   |
|  |   |

# Contacts

#### Mailing Addresses for New Business and Delivery Receipts

New Business National General Accident & Health PO Box 3450 Salt Lake City, UT 84110-3450

Premium Payments National General Accident & Health PO Box 4018 Salt Lake City, UT 84110-4018

#### Agent Portal: ngah.triadtpa.com

#### **Contact Numbers**

Tele-Underwriting: 866-916-8817 Service Center: 866-916-8816 Agency Services: 866-916-8816

#### Fax Numbers

New Business/Tele-Underwriting: 801-812-8212 Claims: 801-812-8185 Service Center: 801-812-8302 Agency Services: 801-812-8302

### **Hours of Operation**

National General Accident & Health administrative operations are located in Salt Lake City, Utah. Hours of operation are based on Mountain Standard Time.

Tele-Underwriting Monday – Friday: 7:00 AM – 6:00 PM. MST

All Other Departments Monday – Friday: 7:00 AM – 5:30 PM. MST

### Introduction

Thank you for partnering with National General Accident & Health for Individual Medicare Supplement insurance. This document has been designed to help you understand the Underwriting process and guidelines used by National General Accident & Health when reviewing applications. This guide contains a general overview of current medical underwriting guidelines and is subject to change at any time.

### **New Business Guidelines**

#### **Eligibility Requirements**

Applicants are eligible to apply for Medicare Supplement insurance if they:

- Are covered under Medicare Part A & B.
- Are 65 years of age or older.
- Are Medicare eligible due to disability in a state requiring under age 65 coverage.

#### **New Business Guidelines**

Applications must be submitted and received at the Home Office within 15 days of the application signature date. Once we receive the application, it will be processed in the order in which it was received. If there are any errors on the application, you will be notified as they are found and corrections will be requested. Any errors will need to be fixed before a policy can be issued.

#### **Effective Date**

Effective dates are limited to the first of the month. All applications must contain a requested effective date. Applications without an effective date selection will be processed with an effective date of the first day of the following month.

Open Enrollment.

- An application may be submitted up to 6 months prior to and 6 months following the first day of the month of the applicant's 65<sup>th</sup> birthday or up to 6 months prior to and 6 months following the date the applicant becomes eligible for Medicare Part B. And;
- The coverage effective date must be on or after the first day of the month of the applicant's 65<sup>th</sup> birthday.

*Guaranteed Issue*: An applicant applying under guaranteed issue rights may request an effective date up to 60 days beyond the application date.

*Underwritten*: An applicant applying outside of open enrollment may request an effective date up to 60 days beyond the application date.

Plan Selection: Refer to the state specific application for availability.

#### Replacements

A replacement takes place when an applicant is terminating existing Medicare Supplement or Medicare Advantage insurance and replacing it with new Medicare Supplement insurance.

National General Accident & Health requires a fully completed application when applying for a replacement policy; all replacements involving Medicare Supplement, Medicare Select or Medicare Advantage insurance MUST include a completed Replacement Notice.

If an applicant has had Medicare Supplement insurance issued by National General Accident & Health within the last 90 days, any new applications will be considered to be a reinstatement application. If more than 90 days has elapsed since prior coverage was in force, then applications will follow normal underwriting rules.

# **Open Enrollment Guidelines**

Applicants who purchase Medicare Supplement insurance during an Open Enrollment period are not required to provide any health history information.

An Open Enrollment period is available for applicants who are:

- Within 6 months of turning age 65.
- Within 6 months of first enrolling in Medicare Part B.
- Now age 65, previously qualified for Medicare due to disability and enrolled in Medicare Part B, now eligible for a second enrollment period.

During this period, National General Accident & Health cannot deny insurance coverage, place conditions on a policy or charge a higher premium due to past medical conditions.

#### **Open Enrollment Guidelines for Applicants Under Age 65**

Some states require that Medicare Supplement Open Enrollment be offered to individuals under age 65 due to disability. Refer to the chart below for details on availability.

| STATE  | UNDER AGE 65 ACCEPTED | PLAN(S) AVAILABLE           |
|--|-----------------------|-----------------------------|
| Arizona, Ohio, Virginia                      | No                    | N/A                         |
| Georgia, Illinois, Colorado,<br>Pennsylvania | Yes                   | All Plans Available from Us |
| North Carolina                               | Yes                   | A or F                      |
| Texas  | Yes                   | А                           |

### **Guaranteed Issue Guidelines**

Medicare Supplement insurance has guidelines in place that allow qualified applicants to enroll in certain plans without being medically underwritten.

An applicant who is age 65 or older may be eligible for guaranteed issue of Medicare Supplement insurance upon the occurrence of certain events that cause the applicant to lose their existing insurance coverage.

# \*Certain documentation is required to be submitted for applicant's applying for guaranteed issue. Coverage will not be issued as guaranteed issue until the required documents are received.

Guaranteed Issue rules and circumstances are complicated and can be difficult to comprehend. Guaranteed Issue scenarios and plan selection may also vary from state to state. Please reference the Guaranteed Issue section of the application for state specific variations or contact our underwriting department for assistance when submitting Guaranteed Issue business.

To assist you in understanding the rules, we have provided a chart outlining the Guaranteed Issue events and what type of proof needs to be submitted with the application when your client is applying for guaranteed issue.

# Refer to the table on pages 5 and 6 regarding Federal Guidelines and State Specific Guidelines for Guaranteed Issue.

#### Federal Guaranteed Issue Guidelines

| RULE   | Submit the following documents   |
|--|--|
| The applicant enrolled in a Medicare Advantage plan,<br>Medicare Select plan or in a program of All-Inclusive Care of<br>the Elderly (PACE) and the plan is terminated, is no longer<br>providing service in their area or the applicant moved out of<br>the area.<br>Applying for Plan A, F, or High F no later than 63 days<br>from the date the applicant's previous coverage ended.  | <ul> <li>If the previous carrier terminated or discontinued the plan:</li> <li>Letter from prior carrier that contains reason for the discontinuation/termination and the term date.</li> <li>The applicant moved out of the provider's service area:</li> <li>Termination letter from prior carrier showing termination date and verification of address change.</li> </ul>   |
| The applicant enrolled under an employee welfare benefit<br>plan that provides benefits that supplement Medicare (such<br>as COBRA, retiree, etc.) and that plan terminates or ceases<br>to provide all such supplement benefits.<br><b>Applying for Plan A, F, or High F no later than 63 days</b><br><b>from the date the applicant's previous coverage ended.</b>   | <ul> <li>Submit a notice of termination or explanation of benefits for a claim denied due to a termination and</li> <li>If the applicant had a retiree plan, submit one of the following: <ol> <li>Termination letter showing it is a retiree plan;</li> <li>Benefit booklet pages showing it is a retiree plan; or</li> <li>Explanation of benefits showing Medicare paid primary.</li> <li>If the applicant had a COBRA plan, submit an election notice or COBRA bill.</li> <li>If the applicant had a group plan secondary to Medicare, submit an explanation of benefits showing medicare paid primary.</li> </ol> </li> </ul> |
| Medicare Supplement insurance terminated because the<br>insurer became insolvent or bankrupt.<br>Applying for Plan A, F, or High F no later than 63 days<br>from the date the applicant's previous coverage ended.   | Letter from provider or Insurance Commissioner showing termination date.   |
| The Medicare Supplement, Medicare Advantage or PACE<br>insurer violated a material provision of the policy or the<br>agent materially misrepresented the plan's provisions in<br>marketing the plan.<br>Applying for Plan A, F, or High F no later than 63 days<br>from the date the applicant's previous coverage ended.  | <ul> <li>Agent Misrepresentation: <ul> <li>Letter from the carrier showing termination date and reason.</li> </ul> </li> <li>Leaving an MA Plan: <ul> <li>Letter from CMS acknowledging misrepresentation.</li> </ul> </li> <li>Leaving a Medicare Supplement: <ul> <li>Letter from the DOI acknowledging misrepresentation and disenrollment.</li> </ul> </li> </ul>  |
| The applicant terminated their National General Accident &<br>Health Medicare Supplement insurance, enrolled in a<br>Medicare Advantage plan, and then voluntarily dis-enrolled<br>within the first 12 months of enrolling. <b>Note: the applicant</b><br><b>may enroll in the National General Accident &amp; Health</b><br><b>Medicare Supplement plan they were previously on.</b><br><b>However, if that plan is not available, they may enroll in</b><br><b>Plan A, F, or High F.</b> | Letter from the prior Medicare Advantage carrier showing termination date.   |
| The applicant joined a Medicare Advantage or PACE plan<br>when they were first eligible for Medicare and dis-enrolled<br>within the first 12 months. <b>Note: the applicant may enroll</b><br><b>in plan A, F, High F or N.</b>  | Letter from prior carrier showing termination date.  |

#### State Specific Guaranteed Issue Guidelines

| STATE                       | RULE  | PLAN(S) AVAILABLE  |
|-----------------------------|---|--------------------|
| Illinois, Ohio,<br>Colorado | Person voluntarily dis-enrolls from an employer sponsored plan that<br>is <i>primary</i> to benefits covered under Medicare | A, F, or High F    |
| Texas                       | No longer eligible for Medicaid   | A, F, or High F    |
| Pennsylvania                | Person voluntarily dis-enrolls from an employer sponsored plan that is <i>primary</i> to benefits covered under Medicare    | A, B, F, or High F |
| Virginia                    | Person dis-enrolls from an employer sponsored plan in which the benefits are reduced substantially                          | A, F, or High F    |
| Colorado, Texas             | Person voluntarily dis-enrolls from a health plan that is <i>primary</i> to benefits covered under Medicare                 | A, F, or High F    |

# Medicare Advantage (MA) Guidelines

Refer to the chart below for information regarding common election periods for Medicare Advantage Plans.

| Election Periods for<br>Medicare Advantage<br>(MA) Plans | Timeframe  | Allows for  |
|--|--|---|
| Initial Enrollment                                       | When an applicant first becomes<br>eligible for Medicare, they can sign up<br>within a 7-month period that starts 3<br>months before the month they turn 65<br>and ends 3 months after the month of<br>their birthday. | <ul> <li>Enrollment selection for an MA plan.</li> <li>Enrollment selection for Medicare<br/>Part D.</li> </ul>   |
| Annual Election Period<br>(AEP)                          | October 15 <sup>th</sup> – December 7 <sup>th</sup>  | <ul> <li>Enrollment selection for an MA plan.</li> <li>Dis-enroll from or change a current<br/>MA plan.</li> <li>Enrollment selection for Medicare<br/>Part D.</li> </ul>   |
| Medicare Advantage<br>Disenrollment Period*              | January 1 <sup>st</sup> – February 14 <sup>th</sup>  | <ul> <li>Dis-enroll from any MA plan and return to Original Medicare.</li> <li>*Does <u>not</u> provide any of the following options:         <ul> <li>Switch from Original Medicare to Medicare Advantage plan.</li> <li>Switch from one Medicare Advantage plan to another.</li> <li>Switch from one Medicare Prescription Drug plan to another.</li> <li>Join, switch or drop a Medicare Medicare Medical Savings Account plan.</li> </ul> </li> </ul> |

#### Medicare Advantage Disenrollment

If applying for Medicare Supplement insurance, there are certain requirements that must be met when the applicant is disenrolling from a Medicare Advantage plan. Underwriting cannot issue a policy unless the specified requirements are met. Refer to the following guidelines to determine what requirements must be satisfied.

| Dis-enrolling during AEP/MADP  | Dis-enrolling outside of AEP/MADP   |
|--|---|
| <ul> <li>Complete Medicare and Insurance information section<br/>on the application</li> <li>Complete a replacement form (NRN-2017)</li> </ul> | <ul> <li>Complete Medicare and Insurance information section<br/>on the application</li> <li>Provide the Home Office with a copy of the applicant's<br/>MA disenrollment notice*</li> <li>Complete a replacement form (NRN-2017)</li> </ul> |

\* National General Accident & Health is not able to issue a policy until the applicant's disenrollment letter has been received in the Home Office; it must be received within 30 days of the application or the policy will be cancelled.

For any further questions regarding MA disenrollment eligibility, contact the State Health Insurance Assistance Program (SHIP) office or call 1-800-Medicare, as each situation presents its own unique set of circumstances.

### **Enrollment Guidelines**

#### Premium

When calculating the premium, utilize the outline of coverage. Premium is calculated as of the requested effective date of the policy.

#### **Risk Classes**

There are two separate underwriting risk classes: Preferred and Standard. Each risk class has a separate premium rate. See table below.

| Preferred                             | Standard                                  |
|---------------------------------------|---|
| Qualify for Coverage;                 | Qualify for Coverage;                     |
| Fall Within Preferred HT/WT Standards | Fall Outside of Preferred HT/WT Standards |
| AND                                   | AND/OR                                    |
| No Tobacco or Nicotine Use            | Use Tobacco or Nicotine Products          |

\*Use of tobacco or nicotine in any form is considered tobacco use (examples: nicotine patch or gum, electronic cigarettes). This rate can be applied for applicants during open enrollment or for those who qualify for guarantee issue in certain states.

#### Standard rates DO NOT apply during Open Enrollment or Guaranteed Issue in the following states:

Illinois and Ohio

#### **Policy Discount**

National General Accident & Health offers a 7% discount for individuals that meet the necessary qualifications. See the chart below for details.

| STATES     | DISCOUNT   |
|------------|--|
| AZ, GA, OH | Available to applicants if for the past 12 months have resided with at least one,<br>but no more than three, other adults who are age 50 or older. If living with another<br>adult who is their legal spouse, domestic partner, or in a Civil Union Partnership<br>we will waive the one- year requirement.  |
| IL         | Available to applicants if for the past 12 months have resided with at least one but<br>no more than three, other adults who are age 50 or older and also have an active<br>National General Accident & Health Medicare Supplement insurance. If living with<br>another adult who is the legal spouse, domestic partner, or in a Civil Union<br>Partnership, we will waive the one-year requirement. |

#### Submitting the Application

National General Accident & Health offers three methods for submitting and completing applications:

- Web Application
- Telephonic Application
- Paper Application

Each application has its own guidelines to follow when submitting for coverage.

#### Web Application (i.e. Electronic Application or eApp)

The Web Application is a digital form to be filled out and submitted through the agent portal. In order to complete an application using the Web Application Process:

- 1. Refer to step 1 & 2 of the Telephonic (Express) Application Process.
- 2. Log on to the agent portal at ngah.triadtpa.com
- 3. Access the eApp by clicking "eApp" on the left hand side of the screen. Complete the application in full.
- 4. Once you have completed the application you will have the option to select the signature option:
  - a. Passphrase Signature
  - b. Docu-Sign
- 5. Once the application has been completed, you will be notified of the decision via email.

For fully underwritten applications, an underwriter will be assigned to the case and may contact your applicant to complete the medical risk assessment if necessary.

Once the application has been completed, you will be notified of the decision via email or you may contact the Underwriting department for a point of sale decision.

For assistance with accessing the agent portal, contact the Agency Services Department at 866-916-8816.

#### **Telephonic Application**

The Telephonic Application is completed, from start to finish, over the phone with a specialist from the National General Accident & Health Tele-Underwriting Department. To complete an application using the Telephonic Application Process, contact Tele-Underwriting at 866-916-8817. Note: ALL Telephonic and Web Applications must be set up to have the premium paid using Bank Draft.

When completing an application using the Telephonic Application Process:

- 1. Pre-qualify the applicant based on the Medical Questions found on Page 3 and 4 (not required if the applicant is applying under Open Enrollment or Guaranteed Issue).
- Review the application with the applicant; you MUST read the required statements in Section G Disclosure. If the client has not been read these statements, the Underwriter will end the call and inform you that the statements must be read by the client to complete the interview.

- 3. Complete the Replacement Notice (NRN-2017) if the applicant is replacing coverage.
- 4. Prepare for the call. When you contact the Tele-Underwriting Department to complete an interview, both you and the applicant will be required to provide certain information:

#### Agent:

- Producer (writing) number.
- Type of plan, effective date of plan.
- Any plan discount information.
- Applicant's current policy information (if the applicant is replacing).

#### Applicant:

- Social Security Number.
- Medicare ID Number or MBI Number (Medicare Card).
- Primary Care Provider information.
- Prescription Medication information.
- Bank Routing & Account number (check book).

5. Contact the Tele-Underwriting Department to complete the phone interview. When completing the phone interview, DO NOT COACH THE APPLICANT. It is recommended that you explain what will take place but you MUST NOT participate in the interview. Our underwriters are trained to identify coaching and, if identified, it will only delay the application process.

Once the interview is complete, send the Home Office a copy of required forms. These forms must be received within 14 days of the application date or commission will be charged back.

#### **Paper Application**

To submit an application using the Paper Application Process:

- 1. Pre-qualify the applicant based on the Medical Questions found on Page 3 and 4 of the application. (Not required if the applicant is applying under Open Enrollment or Guaranteed Issue).
- 2. Complete the entire application.
- 3. Complete the Health Information Authorization (N-HHA-MS).
- 4. If the applicant is replacing coverage: complete the Replacement Notice (NRN- 2017).
- 5. If the applicant is applying during Guaranteed Issue: Complete the Definition of Eligible Person for Guaranteed Issue form (GI-MS).

Once the application has been completed, you can submit the application either by faxing it to the National General Accident & Health New Business Department at 801-812-8212 or by uploading it through the agent portal at ngah.triadtpa.com.

Any application dated outside 30 days from the date the application is received at the National General Accident & Health Home Office will be returned.

In order to accelerate the application process, verify that the application has been completed in full. Try to be as detailed as possible when filling out an application. This will assist in expediting the process.

#### Producer Checklist for Paper Applications

- □ Application is completely filled out.
- □ All Medical Questions have been answered (only required if application is Underwritten).
- Disclosure, Acknowledgements, and Agreement (pg. 5) signed and dated.
- □ HIPAA statement (N-HHA-MS) signed and dated.
- □ Replacement Notice (NRN- 2017) completed and signed (if necessary).
- Definition of Eligible Person for Guaranteed Issue (GI-MS) completed (if necessary).

#### **Application Signature**

All applications require a valid signature in order to be processed.

Web/Telephonic Applications

- Telephonic Applications require a verbal signature.
- Web Applications require Docu-Sign signatures.
- POA signatures are not accepted on Telephonic/Web applications.

**Paper Applications** 

- All Paper applications require the applicant's physical signature.
- POA signatures can be accepted only for OE/GI cases.

#### **Premium Payment**

National General Accident & Health offers two forms of payment for premium charges: Each form of payment has its own guidelines.

- Bank Draft.
- Direct Bill.

#### Bank Draft

Bank draft is available for all forms of applications and is the only option available when completing a Telephonic or Web Application. The payments will be set up to automatically draft from the applicant's bank account. Payments can be set up to be made:

- Monthly.
- Quarterly.
- Semi-Annually.
- Annually.

Bank drafts can be drawn between the 1st day and the 11th day of the month.

For monthly Bank Draft, the "Draft Date" must be within 10 days of the effective date. If the draft date is more than 10 days from the initial premium, we will draft an additional payment in advance.

#### Direct Bill

Direct bill is available for Paper applications. We will process all checks as EFT (Electronic Funds Transfer) with the bank. Cash, post-dated checks, money orders, traveler's checks, agent checks and agency checks will not be accepted. Unless required by law or regulation, checks from a third party payer (such as a foundation or other non-profit) will not be accepted. In some circumstances, checks from a family member or business associate can be accepted.

When completing an application using the Telephonic or Web Application process, the applicant must set up their payments to be automatically drafted from their account. If they wish to have their subsequent payments to be billed to them directly, they are able to do so by contacting National General Accident & Health. Direct bill payments can be set up:

- Quarterly.
- Semi-Annually.
- Annually.

#### **Required Forms**

Each application method has different requirements for forms that need to be submitted to the home office:

Web Application: All forms are built into the Web Application and submitted electronically.

**Telephonic Application** 

 Replacement Notice (NRN- 2017) – if required. State specific forms – if any.

Paper Application: Refer to paper application section on page 9.

## **Agent Responsibilities**

This section does not cover all of the agent's responsibilities. Refer to other sections of the Underwriting Guidelines, the agent contract, and other materials provided.

The Health Insurance Portability and Accountability Act (HIPAA) established requirements and restrictions pertaining to the use and disclosure of Protected Health Information. Please familiarize yourself with both National General Accident & Health's HIPAA Policy and Privacy Policy. Your adherence to federal and state laws and regulations that provide privacy protections is mandatory.

Since the applicant will not be familiar with the underwriting process, it is important for you to read the application and forms to the applicant and/or ask the applicant to read them and ask you for guidance for anything that he/she does not understand.

#### Things That Can Delay the Application Process

- Applicant Coaching: A licensed agent can be an active participant in the Telephonic application process. This
  participation, however, is not permitted during the Medical Information section of the application. If the agent is
  coaching the applicant during the Medical section, the underwriter will warn the agent that the applicant cannot
  receive any assistance in answering questions concerning medical or prescription history. If the agent continues
  to coach the applicant, the underwriter will terminate the call.
- Licensing and appointment issues.
- Missing information on the application.
- Submitting an expired application; application must be received within 30 days of signature date.
- Premium shortage.
- Poor quality copies.

#### **Tips for Completing the Application**

- Ask each question exactly as written.
- Complete the application legibly and in black or blue ink.
- Have the applicant initial and date any correction or mistake.
- If completing a Telephonic or Web application, prepare the applicant for the Telephonic or Web application process. Refer to page 9.
- The primary residence address is the physical address where the applicant lives. A post office box should <u>not</u> be used for the primary residence address. The applicant can also provide an optional mailing address which can be a post office box.

### **Underwriting Concepts**

We review applications in the order in which they are received. Once an application has been received and logged into the Underwriting Department, an underwriter is assigned to the case and the application is reviewed. The underwriter will do their best to process the application with the information provided but additional information may be required in order complete the application process.

Applicant must sign to certify the health questions will be answered to the best of the applicant's memory, and also to acknowledge that the applicant's misrepresentation could result in a denial of benefits and/or rescission of the policy. Information from claims activity, MIB, or other sources could lead to a file review and inquiry to consider if misrepresentations were made at the time of the application.

#### **Medical Underwriting**

Medical underwriting is the process of reviewing the medical history of applicants and comparing that information with established guidelines in order to assess the risk associated with providing insurance to that applicant.

National General Accident & Health's underwriting guidelines take into consideration many different factors, including but not limited to the following:

- Height and weight.
- Current and past medical conditions.
- Diagnosis and prognosis.
- Use of prescription drugs.
- Follow-up required.
- Chronic nature of the disease.

National General Accident & Health collects pharmaceutical information on underwritten Medicare Supplement applications. In order to obtain the pharmaceutical information as requested, all underwritten applications must be submitted with a signed HIPAA Privacy form (N-HHA-MS). Prescription information disclosed on the application will be compared to the additional pharmaceutical information obtained in the underwriting process.

The decision to issue coverage will be made by underwriting based on a review of the application and any additional information received.

#### **Underwriting Appeals**

In the event of an adverse decision, the application could be eligible for reconsideration. Reconsiderations are case specific and should be carefully considered. Agents disputing a decline or rate up are welcome to submit information from the applicant's doctor that disputes the reason for the adverse decision.

Information received from the doctor's letter must be current (dated within 30 days of the application) and must be specific to the health condition we are concerned with. National General Accident & Health reserves the right to request up to three years of medical records to resolve any disputes. Random excerpts from the applicant's medical records will not be accepted. Any expenses to retrieve a doctor's letter or medical records must be covered by the applicant.

#### Reconsiderations

In the event of an adverse decision, reconsiderations can be offered case by case if the underwriter feels the passage of time might lead to a favorable underwriting outcome. Generally at least one year is needed before the applicant can reapply.

#### Reinstatements

When Medicare Supplement insurance lapses and it is within 31 days of the last paid to date, coverage may be automatically reinstated by submitting all outstanding premiums without meeting any underwriting requirements.

When Medicare Supplement insurance lapses and it is not within 31 days of the last paid to date, the client will need to apply for a reinstatement of coverage where all underwriting requirements must be met before the policy can be reinstated.

Reinstatements are subject to claims review and may require a phone interview, MIB and prescription history check. Reinstatements submitted 90 or more days from the date the policy lapsed will not be accepted; after 90 days from the lapse date, a new application must be submitted.

#### Internal Replacement (Conversions):

Insured individuals requesting to modify benefits under their existing Medicare Supplement insurance policy 90 days after their initial approval or insured individuals requesting to modify their rate class from Standard to Preferred, will be required to submit a new application through underwriting. Follow the Paper application steps 1-3 located on Page 9 (a new application fee will also be charged).

The internal replacement process is subject to underwriting which requires a prescription history check, claims history review, MIB, and telephone interview (if required). There are no Guarantee Issue (GI) options available for internal replacements. Once approved, the benefit change will take effect on the first renewal date following the application date. If the conversion is declined, the existing coverage will remain as is.

### **Underwriting Guidelines**

The purpose of our underwriting department is to assess and evaluate the degree of risk associated with offering insurance to an applicant and make an informed decision based on the information received. Applications may be underwritten up until the time the policy goes into effect.

If the applicant has a change in health after the application was signed but before the policy goes into effect, the applicant is required to disclose the change in health. This new information will be factored into the underwriting decision to approve or decline the application.

The main sources of underwriting information are:

- Application
- Prescription Report
- MIB Report
- Telephone Interview

| If any of the following conditions or situations have applied to the applicant in the past 10 years, the application will be declined. |  |  |
|--|--|--|
| AT ANY TIME  |  |  |
| Acquired Immune Deficiency Syndrome (AIDS)   |  |  |
| AIDS Related Complex (ARC)   |  |  |
| ALS (Amyotrophic Lateral Sclerosis)  |  |  |
| Alzheimer's Disease  |  |  |
| Amputation Caused by Disease   |  |  |
| Cognitive or Brain disorder  |  |  |
| Dementia   |  |  |
| Diabetes with Neuropathy or Retinopathy or Uncontrolled Diabetes (see Underwriting Diabetes section)**                                 |  |  |
| Emphysema, COPD or other Chronic Pulmonary Disorder (see Underwriting Pulmonary Disorders section)*                                    |  |  |
| Human Immunodeficiency Virus (HIV) Infection   |  |  |
| Multiple Sclerosis   |  |  |
| Muscular Dystrophy   |  |  |
| Myasthenia Gravis  |  |  |
| Organ Transplant   |  |  |
| Parkinson's Disease  |  |  |
| Scleroderma  |  |  |
| Surgery, Medical Tests, Treatment or Therapy That Has Not Been Performed   |  |  |
| Surgery May Be Required Within Next 12 Months for Cataracts  |  |  |
| Systemic Lupus   |  |  |
| WITHIN THE PAST 24 MO  |  |  |
| Alcoholism or Drug Abuse   |  |  |
| Bipolar or Personality Disorder  |  |  |
| Carotid Artery Disease   |  |  |
| Chronic Kidney Disease Including End Stage Renal Disease   |  |  |
| Chronic Hepatitis  |  |  |
| Cirrhosis  |  |  |
| Congestive Heart Failure   |  |  |
| Coronary Artery Disease  |  |  |
| Crippling or Disabling Arthritis   |  |  |

| WITHIN THE PAST 24 MO (CONT'D)                                   |  |  |
|--|--|--|
| Enlarged Heart   |  |  |
| Heart Attack   |  |  |
| Heart Rhythm Disorders   |  |  |
| Heart Valve Surgery  |  |  |
| Hodgkin's Disease or other Lymphoma                              |  |  |
| Internal Cancer  |  |  |
| Joint Replacement  |  |  |
| Leukemia   |  |  |
| Major Depression   |  |  |
| Melanoma   |  |  |
| Mental or Nervous Disorder requiring psychiatric hospitalization |  |  |
| Osteoporosis with one or more fractures                          |  |  |
| Peripheral Vascular Disease                                      |  |  |
| Rheumatoid Arthritis   |  |  |
| Schizophrenia  |  |  |
| Stroke or Transient Ischemic Attack (TIA)                        |  |  |

#### **Underwriting Diabetes\***

An applicant who has diabetes may or may not be insurable. An applicant who has never had retinopathy or neuropathy and whose recent A1C levels show good control of blood sugar, could be insurable.

A1C, also called hemoglobin A1C, glycosylated hemoglobin or HbA1c, is a common blood test used to diagnose both type 1 and type 2 diabetes. A1C is also used on an ongoing basis to gauge how well the patient is managing the diabetes condition. It reflects the average blood sugar level for the past two to three months. If the applicant remembers A1C levels before the most recent one, ask the applicant to provide the levels and approximate dates in Section F. for Additional Comments.

The use of insulin as a treatment, and the number of units of insulin being taken at the time of the application, is not a determining factor for insurability all by itself. If the applicant is significantly overweight and/or has certain conditions, such as heart disorder or lung disease, the risk is generally uninsurable. The underwriter will consider all of the information in the application as well as information from other sources.

#### **Underwriting Pulmonary Disorders\*\***

An applicant who has emphysema or any other chronic pulmonary (respiratory; lung) disorder other than mild asthma is uninsurable. If the applicant has severe asthma, it is considered a chronic pulmonary disorder and therefore is uninsurable. If the applicant's pulmonary disorder has required treatment with supplemental oxygen or a nebulizer in the past two years, the risk is uninsurable.

#### Build Table –

Applications will be declined for applicants whose weight is below the Minimum Weight or above the Maximum Weight.

| HEIGHT | MINIMUM WEIGHT | PREFERRED WEIGHT | MAXIMUM WEIGHT |
|--------|----------------|------------------|----------------|
| 4'2"   | 54-59          | 60-124           | 125-149        |
| 4'3"   | 56-62          | 63-129           | 130-155        |
| 4'4"   | 59-64          | 65-135           | 136-161        |
| 4'5"   | 60-67          | 68-140           | 141-168        |
| 4'6"   | 63-70          | 71-145           | 146-174        |
| 4'7"   | 65-72          | 73-151           | 152-181        |
| 4'8"   | 67-75          | 76-156           | 157-187        |
| 4'9"   | 70-78          | 79-162           | 163-194        |
| 4'10"  | 72-80          | 81-167           | 168-201        |
| 4'11"  | 75-83          | 84-173           | 174-208        |
| 5'0"   | 77-86          | 87-179           | 180-215        |
| 5'1"   | 80-89          | 90-185           | 186-222        |
| 5'2"   | 83-92          | 93-191           | 192-229        |
| 5'3"   | 85-95          | 96-198           | 199-237        |
| 5'4"   | 88-98          | 99-204           | 205-244        |
| 5'5"   | 91-101         | 102-210          | 211-252        |
| 5'6"   | 93-104         | 105-217          | 218-260        |
| 5'7"   | 96-108         | 109-223          | 224-268        |
| 5'8"   | 99-111         | 112-230          | 231-276        |
| 5'9"   | 102-114        | 115-237          | 238-284        |
| 5'10"  | 105-117        | 118-244          | 245-292        |
| 5'11"  | 108-121        | 122-251          | 252-301        |
| 6'0"   | 111-124        | 125-258          | 259-309        |
| 6'1"   | 114-128        | 129-265          | 266-318        |
| 6'2"   | 117-131        | 132-273          | 274-326        |
| 6'3"   | 121-135        | 136-280          | 281-335        |
| 6'4"   | 124-139        | 140-288          | 289-344        |
| 6'5"   | 127-142        | 143-295          | 296-353        |
| 6'6"   | 130-146        | 147-303          | 304-363        |
| 6'7"   | 134-150        | 151-311          | 312-373        |
| 6'8"   | 137-154        | 155-319          | 320-382        |
| 6'9"   | 140-158        | 159-327          | 328-392        |
| 6'10"  | 144-162        | 163-335          | 336-402        |
| 6'11"  | 147-166        | 167-343          | 344-412        |
| 7'0"   | 151-170        | 171-351          | 352-422        |
| 7'1"   | 155-174        | 175-360          | 361-432        |
| 7'2"   | 158-178        | 179-368          | 369-442        |
| 7'3"   | 162-182        | 183-377          | 378-452        |
| 7'4"   | 166-186        | 187-386          | 387-463        |

## **Drug List Information**

Drug list information is provided to assist agents in the application process. This is a list of the most commonly prescribed medications for declinable conditions. Applicants may be unaware of a condition listed on the application, but prescribed medication may indicate the condition exists and therefore make the applicant not eligible for coverage with the company.

#### **Uninsurable Medications:**

Below is a partial list of uninsurable medications. Please contact underwriting if you are unsure about a medication that does not appear in the list below.

If the medication is on the list below but is being prescribed for a condition not listed below or is being prescribed in an "off-label" situation, the condition may or may not be insurable. However, if the "off-label" condition being treated is on the list of uninsurable health conditions, the risk is not insurable. If the situation is not clear, it is best to contact underwriting in advance of filling out an application.

| Generic                 | Brands   | Used for                                     |  |
|-------------------------|--|--|--|
| abacavir                | Ziagen   | HIV  |  |
| abarelix                | Plenaxis   | cancer                                       |  |
| abciximab               | ReoPro   | heart disorder                               |  |
| acamprosate             | Campral  | alcohol abuse                                |  |
| adalimumab              | Humira   | rheumatoid arthritis                         |  |
| AL-721                  | AL-721   | AIDS, HIV                                    |  |
| albuterol/ipratropium   | DuoNeb, Combivent Respimat                           | COPD   |  |
| alemtuzumab             | Campath, Lemtrada                                    | multiple sclerosis, leukemia                 |  |
| alteplase               | Activase   | heart disorder, stroke                       |  |
| altretamine             | Hexalen  | cancer                                       |  |
| amantadine              | Endantadine, Symmetrel, Symadine                     | Parkinson's                                  |  |
| ambrisentan             | Letairis   | pulmonary hypertension                       |  |
| amiodarone              | Cordarone, Pacerone, Nexterone                       | heart disorder                               |  |
| anakinra                | Kineret  | rheumatoid arthritis                         |  |
| anastrozole             | Arimidex   | cancer                                       |  |
| apomorphine             | Apokyn, Uprima                                       | Parkinson's                                  |  |
| aripripazole            | Abilify, Aristada                                    | schizophrenia                                |  |
| asparaginase            | Elspar   | leukemia                                     |  |
| atazanavir              | Reyataz  | HIV  |  |
| auranofin               | Ridaura  | rheumatoid arthritis                         |  |
| aurothioglucose         | Solganal   | rheumatoid arthritis                         |  |
| aurothiomalate          | Myochrysine, Aurolate                                | severe arthritis                             |  |
| azathioprine            | Imuran, Azasan                                       | rheumatoid arthritis, kidney transplant      |  |
| BCG                     | TheraCyx, Tice BCG                                   | bladder cancer                               |  |
| becaplermin             | Regranex   | diabetic neuropathy                          |  |
| benztropine             | Cogentin   | Parkinson's                                  |  |
| bevacizumab             | Avastin  | cancer                                       |  |
| bicalutamide            | Casodex  | prostate cancer                              |  |
| biperiden hydrochloride | Akineton   | Parkinson's                                  |  |
| bleomycin               | Blenoxane  | cancer                                       |  |
| bromocriptine           | Cycloset, Parlodel                                   | Parkinson's                                  |  |
| busulfan                | Myleran, Busulfex                                    | cancer                                       |  |
| capecitabine            | Xeloda   | cancer                                       |  |
| carbidopa               | Lodosyn  | Parkinson's                                  |  |
| carbidopa/levodopa      | Sinemet, Rytary, Duopa, Atamet, Carbilev,<br>Parcopa | Parkinson's                                  |  |
| carboplatin             | Paraplatin   | cancer                                       |  |
| chlorambucil            | Leukeran   | cancer, kidney disease, rheumatoid arthritis |  |
| chlorotrianisene        | Tace   | cancer                                       |  |

| Generic                            | Brands  | Used for  |
|------------------------------------|---|---|
| chlorpromazine                     | Thorazine   | schizophrenia, psychosis                            |
| cilostazol                         | Pletal  | peripheral vascular disease                         |
| cinacalcet                         | Sensipar  | hyperparathyroidism due to cancer or kidney disease |
| cisplatin                          | Platinol  | cancer  |
| cladribine                         | Leustatin   | leukemia  |
| clopidogrel                        | Plavix  | cardiovascular                                      |
| clozapine                          | Clozaril, FazaClo, Versacloz                                  | schizophrenia                                       |
| cyclophosphamide                   | Cytoxan, Neosar   | cancer, rheumatoid arthritis, lupus                 |
| cycloserine                        | Seromycin   | tuberculosis  |
| cyclosporine                       | Neoral, Sandimmune, Gengraf                                   | organ transplant, cancer, severe arthritis          |
| dalteparin                         | Fragmin   | cardiovascular, cancer                              |
| dantrolene                         | Dantrium, Ryanodex, Revonto                                   | multiple sclerosis                                  |
| darunavir                          | Prezista  | AIDS, HIV   |
| delavirdine                        | Rescriptor  | AIDS, HIV   |
| didanosine                         | Videx, ddl  | AIDS, HIV   |
| dipyridamole                       | Persantine  | cardiovascular                                      |
| dipyridamole/aspirin               | Aggrenox  | stroke, TIA   |
| disulfiram                         | Antabuse  | alcohol abuse                                       |
| donepezil                          | Aricept   | dementia  |
| doxorubicin                        | Adriamycin, Caelyx, Rubex                                     | cancer  |
| dronabinol                         | Marinol, THC  | cancer  |
| efavirenz                          | Sustiva   | AIDS, HIV   |
| emtricitabine                      | Atripla   | AIDS, HIV   |
| emtricitabine                      | Emtriva, Coviracil  | AIDS, HIV   |
| emtricitabine/tenofovir            | Truvada   | HIV   |
|                                    |   | AIDS, HIV   |
| enfuvirtide                        | Fuzeon  |   |
| enoxaparin                         | Lovenox   | peripheral vascular disease                         |
| entacapone                         | Comtan  | Parkinson's   |
| entacapone/levodopa/carbidopa      | Stalevo   | Parkinson's   |
| epoetin alfa                       | Epogen, Procrit, Eprex  | chronic kidney disease                              |
| eptifibatide                       | Integrilin  | heart disorder                                      |
| ergoloid mesylates                 | Hydergine   | dementia  |
| estramustine                       | Emcyt   | cancer  |
| etanercept                         | Enbrel  | severe arthritis                                    |
| ethinyl estradiol                  | Estinyl   | cancer<br>Decking solution                          |
| ethopropazine                      | Parsidol  | Parkinson's   |
| etoposide                          | VePesid, Toposar, Etopophos                                   | cancer  |
| exemestane                         | Aromasin  | cancer  |
| filgrastim                         | Neupogen, Granix, Zarxio                                      | cancer  |
| flecainide                         | Tambocor  | heart disorder                                      |
| fluorourcil                        | Adrucil   | cancer  |
| fluphenazine                       | Modecate, Prolixin, Moditen, Permitil                         | psychosis   |
| flutamide                          | Euflex, Eulexin   | cancer  |
| fondaparinux                       | Arixtra   | vascular disease                                    |
| fosamprenavir                      | Lexiva  | HIV   |
| foscarnet sodium                   | Foscavir  | AIDS, HIV   |
| fulvestrant                        | Faslodex  | cancer  |
| galantamine                        | Razadyne, Reminyl   | dementia  |
| glatiramer                         | Copaxone, Glatopa   | multiple sclerosis                                  |
| gold sodium thiomalate             | Myochrysine, Aurolate   | severe arthritis                                    |
| goserelin                          | Zoladex   | cancer  |
| haloperidol                        | Haldol, Peridol   | psychosis   |
|                                    |   | cardiovascular                                      |
| heparin                            | Calcilean, Calciparine, Hepalean, Liquaemin                   |   |
|                                    | Calcilean, Calciparine, Hepalean, Liquaemin<br>Hydrea, Droxia | cancer  |
| heparin                            |   |   |
| heparin<br>hydroxyurea             | Hydrea, Droxia  | cancer  |
| heparin<br>hydroxyurea<br>imatinib | Hydrea, Droxia<br>Gleevec                                     | cancer<br>cancer                                    |

| Generic                        | Brands  | Used for   |
|--------------------------------|---|--|
| interferon                     | many brands   | AIDS, HIV, cancer, multiple sclerosis,<br>hepatitis  |
| interferon alfa-2a             | Roferon-A   | AIDS, HIV, cancer                                    |
| interferon beta 1a             | Avonex, Rebif   | multiple sclerosis                                   |
| interferon beta 1b             | Betaseron, Extavia  | multiple sclerosis                                   |
| ipratropium                    | Atrovent  | COPD   |
| isoniazid                      | Hyzyd, INH, Laniazid, Nydrazid, Rimifon,<br>Tubizid   | tuberculosis   |
| lamivudine                     | Combivir, 3TC, Epivir   | AIDS   |
| lamivudine/zidovudine/abacavir | Trizivir  | HIV  |
| letrozole                      | Femara  | cancer   |
| leucovorin                     | Wellcovorin   | cancer   |
| leuprolide                     | Lupron, Eligard   | cancer   |
| levamisole hydrochloride       | Ergamisol   | cancer   |
| levodopa                       | Larodopa, Dopar, L-Dopa   | Parkinson's  |
| lomustine                      | Gleostine, CCNU   | cancer   |
| lopinavir                      | Kaletra   | HIV  |
| loxapine                       | Loxitane  | schizophrenia  |
| maraviroc                      | Selzentry   | HIV  |
| medroxyprogesterone acetate    | Depo-Provera, Provera, Amen, Curretab,<br>Cycrin  | cancer   |
| megestrol                      | Megace  | cancer   |
| melphalan                      | Alkeran   | cancer   |
| memantine                      | Namenda   | dementia   |
| methadone                      | Methadose, Dolophine  | severe pain  |
| methotrexate                   | Trexall, Rheumatrex, Rasuvo, Otrexup  | severe arthritis, cancer                             |
| mitomycin                      | Mutamycin   | cancer   |
| mitoxantrone                   | Novantrone  | multiple sclerosis, cancer                           |
| morphine                       | Contin, Avinza, Depodur, Duramorph,<br>Infumorph, Astramorph, Kadian, Oramorph,<br>Rapi-Ject, Roxanol | severe pain  |
| mycophenolate                  | CellCept, Myfortic  | myasthenia gravis, organ transplant                  |
| naltrexone                     | ReVia, Vivitrol, Depade   | opioid or alcohol detox                              |
| natalizumab                    | Tysabri   | multiple sclerosis                                   |
| nebulizer device               |   | respiratory / pulmonary disorders                    |
| nelfinavir                     | Viracept  | AIDS, HIV  |
| neostigmine                    | Prostigmin, Bloxiverz   | Myasthenia Gravis                                    |
| nesiritide                     | Natrecor  | congestive heart disorder failure                    |
| nevirapine                     | Viramune  | AIDS, HIV  |
| nilutamide                     | Nilandron   | cancer   |
| nitroglycerine                 | glyceryl trinitrate, Nitrol, Nitro Bid, Tridil, NTG   | heart disorder                                       |
| nitroglycerine transdermal     | NitroDur, Minitran, Deponit, Nitrocine  | heart disorder                                       |
| olanzapine                     | Zyprexa   | schizophrenia  |
| ondansetron                    | Zofran  | cancer   |
| oxygen                         |   | Respiratory / pulmonary disorder                     |
| paliperidone                   | Invega  | schizophrenia  |
| penicillamine                  | Cuprimine, Depen  | rheumatoid arthritis, disease of liver<br>or kidneys |
| pergolide mesylate             | Permax  | Parkinson's  |
| perphenazine                   | Trilafon  | schizophrenia  |
| pimozide                       | Orap  | schizophrenia  |
| pramipexole                    | Mirapex   | Parkinson's  |
| procainamide                   | Procanbid, Pronestyl  | heart disorder                                       |
| prochlorperazine               | Compazine   | psychosis  |
| procyclidine                   | Kemadrin  | Parkinson's  |
| pyridostigmine                 | Mestinon, Regonol   | Myasthenia Gravis                                    |
| quetiapine                     | Seroquel  | schizophrenia  |
| quinidine                      | Quinaglute, Quinidex  | heart disorder                                       |
| rasagiline                     | Azilect   | Parkinson's  |
| riluzole                       | Rilutek   | ALS - amyotrophic lateral sclerosis                  |

| Generic         | Brands                               | Used for                            |
|-----------------|--------------------------------------|-------------------------------------|
| risperidone     | Risperdal                            | schizophrenia, psychosis            |
| ritonavir       | Norvir                               | AIDS, HIV                           |
| rituximab       | Rituxan                              | non-Hodgkin lymphoma                |
| rivaroxaban     | Xarelto                              | cardiovascular                      |
| rivastigmine    | Exelon                               | dementia                            |
| ropinirole      | Requip                               | Parkinson's                         |
| rotigotine      | Neupro                               | Parkinson's                         |
| saquinavir      | Invirase, Fortovase                  | AIDS, HIV                           |
| selegiline      | Carbex, Eldepryl, Zelapar            | Parkinson's                         |
| sotalol         | Betapace, Sorine, Sotylize           | heart disorder                      |
| stavudine       | Zerit, d4T                           | AIDS, HIV                           |
| streptozocin    | Zanosar                              | cancer                              |
| tacrine         | Cognex                               | dementia                            |
| tacrolimus      | Prograf, Hecoria, Astagraf, Envarsus | myasthenia gravis, organ transplant |
| tamoxifen       | Soltamox                             | cancer                              |
| tenofovir       | Viread                               | AIDS, HIV                           |
| testolactone    | Teslac                               | cancer                              |
| thioridazine    | Mellaril                             | psychosis, dementia                 |
| thiotepa        | Tespa, Thioplex                      | cancer                              |
| thiothixene     | Navane                               | psychosis                           |
| ticlopidine     | Ticlid                               | cardiovascular                      |
| tiotropium      | Spiriva                              | COPD                                |
| tipranavir      | Aptivus                              | AIDS, HIV                           |
| tirofiban       | Aggrastat                            | heart disorder, kidney              |
| tolcapone       | Tasmar                               | Parkinson's                         |
| toremifene      | Fareston                             | cancer                              |
| trastuzumab     | Herceptin                            | cancer                              |
| treprosinil     | Tyvaso, Remodulin, Orenitram         | pulmonary hypertension              |
| trifluoperazine | Stelazine                            | schizophrenia, psychosis            |
| trihexyphenidyl | Artane, Trihex                       | Parkinson's                         |
| triptorelin     | Trelstar                             | cancer                              |
| valganiciclovir | Valcyte                              | cytomegalovirus disease, HIV        |
| vincristine     | Oncovin, Vincasar                    | cancer                              |
| warfarin        | Coumadin, Jantoven                   | cardiovascular                      |
| zalcitabine     | Hivid, ddC                           | AIDS, HIV                           |
| zidovudine      | AZT, ZDV, Retrovir                   | AIDS, HIV, hepatitis                |
| ziprasidone     | Geodon                               | schizophrenia, psychosis            |
| zoledronic acid | Reclast, Zometa                      | hypercalcemia caused by cancer      |

Any questions concerning medications should be directed to the Underwriting Department.



For Agent and Home Office use only

NGAH\_MEDSUP 05/2018 © 2018. National Health Insurance Company. All Rights Reserved.

National General Accident & Health markets products underwritten by National Health Insurance Company, Integon National Insurance Company and Integon Indemnity Corporation.